Published On:July 4, 2017, 9:39 am
Intranasal drug delivery systems administer drugs through nasal route. In other words, the drugs administered through the nose. The nasal route is covered by a thin mucous membrane which is well vascularized. Thus, a drug particle can be transmitted quickly across the solo epithelial cell layer straight to the blood stream avoids gastrointestinal destruction and hepatic first pass metabolism. The result is often achieved within 4-5 minutes for smaller drug particles.
Intranasal drug delivery can, therefore, be used as an option to oral administration for example capsules and tablets if a quick effect is desired or if the drug is extensively dissolute in the liver. Drugs which are inadequately absorbed orally can also be given by nasal route. Intranasal medication’s rates of absorption and plasma concentrations are typically better than subcutaneous or intramuscular routes. Intranasal Drugs may be dictated for acute or chronic disease treatments and include pain relief drugs, antibiotics, vasoconstrictors, snuffs, calcium supplements and antihistamines, local anesthetics and others. These drugs are administered in various forms like drops, nasal sprays, ointments, and solutions.
In 2016, the global intranasal drug delivery device market was valued approximately USD 44 billion. It is expected to garner USD 64.20 by end of 2022. The compound annual growth rate is forecasted to be 6.5% during the forecast period of 2017 to 2022. The global market industry for intranasal drug delivery is growing at a considerable rate due to rising research and development in this field, high acceptance rate for this drug delivery mode. Use of nasal route for delivering drug leads to increase in efficacy of the drug. Intranasal drug delivery is also used for management of depression and anxiety.
Worldwide, North America is the biggest market for intranasal drug delivery device and is followed by Asia-Pacific and Europe. Developing countries of Latin America, Asia, Africa and the Middle East are expected to spectator utmost market growth due to the progress of the economy, enhanced healthcare infrastructure, increasing penetration of medical insurances and growing incidences of acute and chronic diseases. However, drug formulation breakdown and market recalls, and technological hurdle may present a challenge to the growth of this market industry.
The key market players of the Global Intranasal Drug Delivery Device Market are Medinvent Ltd, Marina Biotech, Teleflex Incorporated, SNBL USA, Ltd., Johnson & Johnson, Inc., Aegis Therapeutics LLC, Aptar Group, Inc., Mystic Pharmaceuticals, Dickinson and Company, Kurve Technology, Alchemy Pharmatech Ltd, Alza Corporation, AstraZeneca PLC., MedImmune, Inc., Baxter International, Inc., Becton, GlaxoSmithKline PLC, Inc., Valeant Pharmaceuticals International, Inc. , Novartis AG, Pfizer Inc., Merck & Co. , Rexam PLC and OptiNose. According to product types, the market industry is split into; Nasal sprays, Ointments, and Solutions. By application, the market is classified as; Vaccines, Analgesic, Osteoporosis, Pain management, Allergic Infections and Sexual dysfunction. Geographically, the global market is segmented into regions which are; Southeast Asia, Latin America, North America, Europe, Asia-Pacific, Middle East, Africa and rest of the world.
We will be happy to help you find what you need. Please write to us: